Global Infectious Coryza Vaccine 麻豆原创 Research Report 2023

Publication ID:

PB504244322

Publication Date:

May 4, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Infectious Coryza Vaccine is used to prevent infectious rhinitis in chickens caused by Avian bacillus paragallinarum. The method is subcutaneous injection on the back of the neck.
Highlights
The global Infectious Coryza Vaccine market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Infectious Coryza Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Infectious Coryza Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Infectious Coryza Vaccine include Zoetis, Merck, Boehringer Ingelheim, Ceva Sant茅 Animale, Qilu Animal Health Products Co., Ltd., Tianjin Ruipu Biotechnology Co., Ltd., Harbin Pharmaceutical Group, Plyco Bioengineering Co., Ltd. and Qingdao Yibang Biological Engineering Co., Ltd., etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Infectious Coryza Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Infectious Coryza Vaccine.
The Infectious Coryza Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Infectious Coryza Vaccine market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Infectious Coryza Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Zoetis
Merck
Boehringer Ingelheim
Ceva Sant茅 Animale
Qilu Animal Health Products Co., Ltd.
Tianjin Ruipu Biotechnology Co., Ltd.
Harbin Pharmaceutical Group
Plyco Bioengineering Co., Ltd.
Qingdao Yibang Biological Engineering Co., Ltd.
Shandong Lvdu Biological Technology Co., Ltd.
Shandong Huahong Biological Engineering Co., Ltd.
Segment by Type
Monovalent Vaccine
Bivalent Vaccine
Trivalent Vaccine
Segment by Application
Retail
Online Sale
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Infectious Coryza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Infectious Coryza Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Infectious Coryza Vaccine 麻豆原创 Overview
1.1 Product Overview and Scope of Infectious Coryza Vaccine
1.2 Infectious Coryza Vaccine Segment by Type
1.2.1 Global Infectious Coryza Vaccine 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Monovalent Vaccine
1.2.3 Bivalent Vaccine
1.2.4 Trivalent Vaccine
1.3 Infectious Coryza Vaccine Segment by Application
1.3.1 Global Infectious Coryza Vaccine 麻豆原创 Value by Application: (2023-2029)
1.3.2 Retail
1.3.3 Online Sale
1.3.4 Others
1.4 Global Infectious Coryza Vaccine 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Infectious Coryza Vaccine Revenue 2018-2029
1.4.2 Global Infectious Coryza Vaccine Sales 2018-2029
1.4.3 Global Infectious Coryza Vaccine 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Infectious Coryza Vaccine 麻豆原创 Competition by Manufacturers
2.1 Global Infectious Coryza Vaccine Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Infectious Coryza Vaccine Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Infectious Coryza Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Infectious Coryza Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Infectious Coryza Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Infectious Coryza Vaccine, Product Type & Application
2.7 Infectious Coryza Vaccine 麻豆原创 Competitive Situation and Trends
2.7.1 Infectious Coryza Vaccine 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Infectious Coryza Vaccine Players 麻豆原创 Share by Revenue
2.7.3 Global Infectious Coryza Vaccine 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Infectious Coryza Vaccine Retrospective 麻豆原创 Scenario by Region
3.1 Global Infectious Coryza Vaccine 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Infectious Coryza Vaccine Global Infectious Coryza Vaccine Sales by Region: 2018-2029
3.2.1 Global Infectious Coryza Vaccine Sales by Region: 2018-2023
3.2.2 Global Infectious Coryza Vaccine Sales by Region: 2024-2029
3.3 Global Infectious Coryza Vaccine Global Infectious Coryza Vaccine Revenue by Region: 2018-2029
3.3.1 Global Infectious Coryza Vaccine Revenue by Region: 2018-2023
3.3.2 Global Infectious Coryza Vaccine Revenue by Region: 2024-2029
3.4 North America Infectious Coryza Vaccine 麻豆原创 Facts & Figures by Country
3.4.1 North America Infectious Coryza Vaccine 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Infectious Coryza Vaccine Sales by Country (2018-2029)
3.4.3 North America Infectious Coryza Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Infectious Coryza Vaccine 麻豆原创 Facts & Figures by Country
3.5.1 Europe Infectious Coryza Vaccine 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Infectious Coryza Vaccine Sales by Country (2018-2029)
3.5.3 Europe Infectious Coryza Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Infectious Coryza Vaccine 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Infectious Coryza Vaccine 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Infectious Coryza Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Infectious Coryza Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Infectious Coryza Vaccine 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Infectious Coryza Vaccine 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Infectious Coryza Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Infectious Coryza Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Infectious Coryza Vaccine 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Infectious Coryza Vaccine 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Infectious Coryza Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Infectious Coryza Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Infectious Coryza Vaccine Sales by Type (2018-2029)
4.1.1 Global Infectious Coryza Vaccine Sales by Type (2018-2023)
4.1.2 Global Infectious Coryza Vaccine Sales by Type (2024-2029)
4.1.3 Global Infectious Coryza Vaccine Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Infectious Coryza Vaccine Revenue by Type (2018-2029)
4.2.1 Global Infectious Coryza Vaccine Revenue by Type (2018-2023)
4.2.2 Global Infectious Coryza Vaccine Revenue by Type (2024-2029)
4.2.3 Global Infectious Coryza Vaccine Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Infectious Coryza Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Infectious Coryza Vaccine Sales by Application (2018-2029)
5.1.1 Global Infectious Coryza Vaccine Sales by Application (2018-2023)
5.1.2 Global Infectious Coryza Vaccine Sales by Application (2024-2029)
5.1.3 Global Infectious Coryza Vaccine Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Infectious Coryza Vaccine Revenue by Application (2018-2029)
5.2.1 Global Infectious Coryza Vaccine Revenue by Application (2018-2023)
5.2.2 Global Infectious Coryza Vaccine Revenue by Application (2024-2029)
5.2.3 Global Infectious Coryza Vaccine Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Infectious Coryza Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Zoetis
6.1.1 Zoetis Corporation Information
6.1.2 Zoetis Description and Business Overview
6.1.3 Zoetis Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Zoetis Infectious Coryza Vaccine Product Portfolio
6.1.5 Zoetis Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Merck Infectious Coryza Vaccine Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Boehringer Ingelheim
6.3.1 Boehringer Ingelheim Corporation Information
6.3.2 Boehringer Ingelheim Description and Business Overview
6.3.3 Boehringer Ingelheim Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Boehringer Ingelheim Infectious Coryza Vaccine Product Portfolio
6.3.5 Boehringer Ingelheim Recent Developments/Updates
6.4 Ceva Sant茅 Animale
6.4.1 Ceva Sant茅 Animale Corporation Information
6.4.2 Ceva Sant茅 Animale Description and Business Overview
6.4.3 Ceva Sant茅 Animale Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Ceva Sant茅 Animale Infectious Coryza Vaccine Product Portfolio
6.4.5 Ceva Sant茅 Animale Recent Developments/Updates
6.5 Qilu Animal Health Products Co., Ltd.
6.5.1 Qilu Animal Health Products Co., Ltd. Corporation Information
6.5.2 Qilu Animal Health Products Co., Ltd. Description and Business Overview
6.5.3 Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Product Portfolio
6.5.5 Qilu Animal Health Products Co., Ltd. Recent Developments/Updates
6.6 Tianjin Ruipu Biotechnology Co., Ltd.
6.6.1 Tianjin Ruipu Biotechnology Co., Ltd. Corporation Information
6.6.2 Tianjin Ruipu Biotechnology Co., Ltd. Description and Business Overview
6.6.3 Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Product Portfolio
6.6.5 Tianjin Ruipu Biotechnology Co., Ltd. Recent Developments/Updates
6.7 Harbin Pharmaceutical Group
6.6.1 Harbin Pharmaceutical Group Corporation Information
6.6.2 Harbin Pharmaceutical Group Description and Business Overview
6.6.3 Harbin Pharmaceutical Group Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Harbin Pharmaceutical Group Infectious Coryza Vaccine Product Portfolio
6.7.5 Harbin Pharmaceutical Group Recent Developments/Updates
6.8 Plyco Bioengineering Co., Ltd.
6.8.1 Plyco Bioengineering Co., Ltd. Corporation Information
6.8.2 Plyco Bioengineering Co., Ltd. Description and Business Overview
6.8.3 Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio
6.8.5 Plyco Bioengineering Co., Ltd. Recent Developments/Updates
6.9 Qingdao Yibang Biological Engineering Co., Ltd.
6.9.1 Qingdao Yibang Biological Engineering Co., Ltd. Corporation Information
6.9.2 Qingdao Yibang Biological Engineering Co., Ltd. Description and Business Overview
6.9.3 Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio
6.9.5 Qingdao Yibang Biological Engineering Co., Ltd. Recent Developments/Updates
6.10 Shandong Lvdu Biological Technology Co., Ltd.
6.10.1 Shandong Lvdu Biological Technology Co., Ltd. Corporation Information
6.10.2 Shandong Lvdu Biological Technology Co., Ltd. Description and Business Overview
6.10.3 Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Product Portfolio
6.10.5 Shandong Lvdu Biological Technology Co., Ltd. Recent Developments/Updates
6.11 Shandong Huahong Biological Engineering Co., Ltd.
6.11.1 Shandong Huahong Biological Engineering Co., Ltd. Corporation Information
6.11.2 Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Description and Business Overview
6.11.3 Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio
6.11.5 Shandong Huahong Biological Engineering Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Infectious Coryza Vaccine Industry Chain Analysis
7.2 Infectious Coryza Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Infectious Coryza Vaccine Production Mode & Process
7.4 Infectious Coryza Vaccine Sales and 麻豆原创ing
7.4.1 Infectious Coryza Vaccine Sales Channels
7.4.2 Infectious Coryza Vaccine Distributors
7.5 Infectious Coryza Vaccine Customers
8 Infectious Coryza Vaccine 麻豆原创 Dynamics
8.1 Infectious Coryza Vaccine Industry Trends
8.2 Infectious Coryza Vaccine 麻豆原创 Drivers
8.3 Infectious Coryza Vaccine 麻豆原创 Challenges
8.4 Infectious Coryza Vaccine 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Zoetis
Merck
Boehringer Ingelheim
Ceva Sant茅 Animale
Qilu Animal Health Products Co., Ltd.
Tianjin Ruipu Biotechnology Co., Ltd.
Harbin Pharmaceutical Group
Plyco Bioengineering Co., Ltd.
Qingdao Yibang Biological Engineering Co., Ltd.
Shandong Lvdu Biological Technology Co., Ltd.
Shandong Huahong Biological Engineering Co., Ltd.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.